Index falls as earnings results weigh; pound above $1.33, Bodycote soars
On Monday, Raymond (NSE:RYMD) James adjusted its price target for Colgate-Palmolive Company (NYSE:CL) shares, reducing it to $105 from the previous $110, while maintaining an Outperform rating. Currently trading at $86.70, near its 52-week low of $82.68, the stock has seen a 4.09% decline year-to-date. The revision follows a reported sales deceleration in Q4 that was more significant than expected. According to InvestingPro analysis, the company appears fairly valued at current levels.
The firm’s analyst cited a cautious approach entering 2025 due to the recent sales performance but emphasized the company’s long-term attractiveness. The company maintains impressive gross profit margins of 60.6% and has demonstrated strong shareholder returns, having raised its dividend for 35 consecutive years. According to the analyst, Colgate-Palmolive’s flexible operating structure, strong market shares, and increased household penetration are key factors that position the company for consistent sales and profit growth over time.
Despite the reduction in the price target, the analyst reiterated confidence in Colgate-Palmolive’s ability to leverage investments for future growth. The company’s efforts to streamline operations through their Funding the Growth initiative are expected to accelerate savings, which could offset potential impacts from new tariffs on goods imported from Mexico and China, such as toothpaste and toothbrushes.
The analyst believes that the effect of these new tariffs on Colgate-Palmolive’s annualized earnings per share (EPS) should be minimal. The rationale is that the company’s cost-saving measures will likely mitigate any negative effects from the tariffs, allowing Colgate-Palmolive to maintain its financial health.
In summary, while acknowledging the short-term challenges faced by Colgate-Palmolive, Raymond James continues to see a positive outlook for the company. The firm’s maintained Outperform rating reflects a belief in Colgate-Palmolive’s strategic positioning and its potential for sustained growth despite current market headwinds.
In other recent news, Colgate-Palmolive has experienced several significant developments. The consumer goods giant reported fourth-quarter earnings per share of $0.91, slightly surpassing expectations. However, the company’s organic sales growth of 4.3% did not meet the anticipated 5.9% projection. Colgate-Palmolive also reported impressive gross profit margins of 60.4% and generated $20.1 billion in revenue over the last twelve months.
Among other highlights, Colgate’s Hill’s pet nutrition brand saw a notable 25% growth in the fourth quarter of 2024, contributing significantly to the company’s overall growth. Meanwhile, Raymond James maintained its Outperform rating on Colgate-Palmolive with a steady price target of $110. In contrast, both Stifel and Deutsche Bank (ETR:DBKGn) have adjusted their stock targets for the company to $95, maintaining a hold rating.
These recent developments come amid anticipated foreign exchange headwinds and a slowdown in certain global markets. In response, Colgate-Palmolive announced it would implement pricing adjustments in Latin America starting in the first quarter. As investors continue to monitor these developments, the company remains focused on its growth strategy heading into 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.